Concepedia

Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin

Helen Gu, Catherine Dutreix, Sam Rebello, Taoufik Ouatas, Lai Wang, Dung Yu Chun, Heidi J. Einolf, Handan He

Drug Metabolism and Disposition · 2017 · 33 citations · 32 references

DOIFull text

Open access

Concepts

References

32

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Richard M. Stone, Daniel J. DeAngelo, Virginia M. Klimek et al. · Blood · 2004 · 660 citations · Full text

, , +14

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Ellen Weisberg, Christina Boulton, Louise Kelly et al. · Cancer Cell · 2002 · 602 citations · Full text

, , +14

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 502 citations · Full text

, , +17

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

Jason Gotlib, Hanneke C. Kluin‐Nelemans, Tracy I. George et al. · New England Journal of Medicine · 2016 · 478 citations · Full text

, , +16

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

Christina A. Meyers, Maher Albitar, Elihu H. Estey · Cancer · 2005 · 460 citations

, , +16